Mistry S

Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.

7 papers

ArticlePsilocybin

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.

Kirlić N, Atli M, Mistry S +2

Europe PMC2026
ArticlePsilocybin

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2026
ArticlePsilocybin

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2025
ArticlePsilocybin

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.

Marwood L, Croal M, Mistry S +4

Europe PMC2024
ArticlePsilocybin

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

Goodwin G, Marwood L, Mistry S +6

Europe PMC2023
ArticlePsilocybin

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM, Croal M, Feifel D +11

Europe PMC2023
ArticlePsilocybin

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.

Rucker JJ, Marwood L, Ajantaival RJ +12

Europe PMC2022